Down-selection of the var2csa dbl1-2 expressed in e. coli as a lead antigen for placental malaria vaccine development

HIGHLIGHTS

• who: Arnaud Chêne from the (UNIVERSITY) have published the research work: Down-selection of the VAR2CSA DBL1-2 expressed in E. coli as a lead antigen for placental malaria vaccine development, in the Journal: (JOURNAL) of 26/01/2018
• what: The aim of the work within the PRIMALVAC project is therefore to obtain a proof of concept that a VAR2CSA-based vaccine can be designed for human use and can induce long lasting or rapidly boosted immune_responses producing strain-transcending and crossinhibitory antibodies crucial for clinical protection.
• how: The results are therefore . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.